Sign in

Pain in neurologic disease: Guillain-Barré, multiple sclerosis and Parkinson

Neuropathic pain · C8 · Reviewed by a board-certified pain physician on November 2, 2026

Bottom line

Pain is common in neurologic disease and often follows the disease's own pattern: Guillain-Barré pain can come before weakness, multiple sclerosis can cause secondary trigeminal neuralgia, and Parkinson pain often tracks levodopa off periods.

Key points

  1. Guillain-Barré pain is frequent and early. Weakness usually starts in the legs with reduced reflexes; pain is frequent, can be muscular, radicular or neuropathic, and severe diffuse pain can precede the onset of weakness 1.
  2. Pain persists through the course. In a prospective cohort of 156 patients, 36% had pain in the 2 weeks before weakness, 66% in the acute phase and 38% after 1 year 2.
  3. Watch breathing in the first week. Up to 22% of patients need mechanical ventilation within the first week, so those at risk of respiratory failure must be identified early 1.
  4. Image every trigeminal neuralgia. The European Academy of Neurology recommends MRI with three high-resolution sequences because no clinical characteristic can exclude secondary trigeminal neuralgia 3.
  5. Multiple sclerosis is a classified cause. ICHD-3 lists trigeminal neuralgia attributed to multiple sclerosis among the secondary forms 4.
  6. Parkinson pain follows motor fluctuations. Classifications include off-period pain and painful dystonia, such as early-morning dystonia, in patients with fluctuating responses to levodopa 5.

Watch for

Severe back or limb pain with progressive bilateral weakness and reduced or absent reflexes suggests Guillain-Barré syndrome; monitor for respiratory insufficiency rather than treating it as radiculopathy 1.

High-yield for the exam

  • Guillain-Barré weakness typically starts in the legs; reflexes are reduced or absent in most patients at presentation and in almost all at nadir 1.
  • Maximum disability is typically reached within 2 weeks; reaching it within 24 hours or after 4 weeks suggests another diagnosis 1.
  • Young children with Guillain-Barré syndrome may present with poorly localized pain, refusal to bear weight or an unsteady gait 1.
  • Signs of imminent respiratory insufficiency include breathlessness at rest or while talking, inability to count to 15 in one breath and accessory muscle use 1.
  • Mean pain intensity was highest in patients with sensory disturbances and in severely affected patients 2.
  • Secondary trigeminal neuralgia is generally treated like primary, with carbamazepine or oxcarbazepine as first-choice drugs 3.
  • Pain affects 68–85% of people with Parkinson disease and is underdiagnosed and undertreated 5.
  • Levodopa reversed the lower pain threshold of the off state, and rotigotine gave a 2-fold improvement in fluctuation-related pain versus placebo 5.

Numbers to know

Item Value
Guillain-Barré pain before weakness 36% 2
Pain in the acute phase 66% 2
Pain at 1 year 38% 2
Ventilation in the first week Up to 22% 1
Vital capacity signalling imminent failure Below 15–20 mL/kg or 1 L 1
Pain prevalence in Parkinson disease 68–85% 5

Common traps

  • Attributing back and leg pain with areflexic weakness to disc disease 1.
  • Skipping MRI because trigeminal attacks look typical 3.
  • Adding neuropathic drugs for Parkinson pain that tracks the timing of levodopa doses 5.
  • Assuming Guillain-Barré pain ends as strength returns; over a third still have pain at 1 year 2.

Practise this topic

3 more questions on this topic in the full question bank, with explanations and sources.

Sources

  1. Leonhard SE, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol, 2019. pmc.ncbi.nlm.nih.gov/articles/PMC6821638/
  2. Ruts L, et al. Pain in Guillain-Barre syndrome: a long-term follow-up study. Neurology, 2010. pubmed.ncbi.nlm.nih.gov/20861454/
  3. Bendtsen L, et al. European Academy of Neurology guideline on trigeminal neuralgia. Eur J Neurol, 2019. pubmed.ncbi.nlm.nih.gov/30860637/
  4. International Headache Society. ICHD-3: 13.1 Pain attributed to a lesion or disease of the trigeminal nerve. ichd-3.org, accessed 2026. ichd-3.org/13-painful-cranial-neuropathies-and-other-facial-
  5. Lawn T, et al. Pain in the neurodegenerating brain: insights into pharmacotherapy for Alzheimer disease and Parkinson disease. Pain, 2021. pmc.ncbi.nlm.nih.gov/articles/PMC7977618/

Related topics

Independent study material for the ABA Pain Medicine exam, written and reviewed by a board-certified pain physician. Not medical advice; not affiliated with the American Board of Anesthesiology.